mardi 12 mars 2019

Onco Actu du 12 mars 2019


1. BIOLOGIE



Buffalo gave us spicy wings and the ‘book of life.’ Here’s why that’s undermining personalized medicine [STAT]










Study of rare ovarian cancer sheds light on epigenetic cancer process [Dana-Farber Cancer Institute]











1.1 BIOLOGIE - GÈNES



New gene hunt reveals potential breast cancer treatment target [University of Queensland]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Trump wants the e-cigarette industry to pay $100 million a year in user fees [Washington Post]











Trump proposes e-cigarette user fee to combat youth usage [Reuters]











4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Colon Cancer Screening Can Save Your Life [NY Times]










4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Third of under-30s in Wales snub cervical smear tests [BBC News]











4.9 DÉP., DIAG. & PRONO. - SEIN



Many Families With High Breast Cancer Risk Await a Genetic Explanation [Discover]











5. TRAITEMENTS



Cancer Patients Are Getting Robotic Surgery. There’s No Evidence It’s Better. [NY Times]










5.10 TRAITEMENTS - ESSAIS



Unreported clinical trial of the week: Study of colorectal cancer patients with either regorafenib or standard of care after adjuvant FOLFOX (NCT02425683) [BMJ]











5.12 IMMUNOTHÉRAPIES



Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer [NCI]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres [EndPoints]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



French biotech Cellectis picks U.S. for commercial CAR-T production [Fierce Pharma]











Cellectis to bring CAR-T manufacturing in-house with new plants [Cellectis]











Ask the Experts: how is CAR-T revolutionizing oncology? (Part I: logistics of production and administration) [Oncology Central]










5.12.6 IMMUNOTHÉRAPIES - AMM



Roche's I-O drug Tecentriq picks up key first-in-class breast cancer nod [Fierce Pharma]











FDA Approves First Immunotherapeutic for Breast Cancer [Cancer Research Catalyst]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma [Pharma Times]











Hospitals are saving lives with CAR-T. Getting paid is another story [STAT]










5.2 PHARMA



Stemline licenses RET inhibitor from U.K. cancer group [Fierce Biotech]











Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline [Stemline]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Does Bristol-Myers have a plan B if activists scuttle its Celgene buy? [Fierce Pharma]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin® [Pfizer]











FDA approves Pfizer's biosimilar to Roche's Herceptin [Reuters]











6.10.1 POLITIQUES (USA)



Trump budget pitches capping seniors’ out-of-pocket drug costs, cutting NIH funding [STAT]











Trump seeks big cuts to science funding — again [Nature











Trump proposal would slash total cancer funding while boosting pediatric cancer research [Washington Post]











Trump once again requests deep cuts in U.S. science spending [Science]











6.13 SOINS PALLIATIFS



Specialist cancer survivorship: the changing face of palliative care? [BMJ]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



GoFundMe should stop embracing and promoting unproven clinical research [STAT]











6.7.1 IA/BIOINFORMATIQUE



How algorithms could bring empathy back to medicine [Nature]










How Artificial Intelligence Could Transform Medicine [NY Times]